Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

“Our findings indicate that the vaccine provided a significant enhanced level of protection against these infections in the ...

SAN FRANCISCO -- Incorporating the recently approved bispecific antibody zanidatamab (Ziihera) into first-line treatment for ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.